ArticleJournal of translational medicine2025
Multi-modal integration of histopathology and transcriptomics reveals STAB1
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The CSF1Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColon adenocarcinoma (COAD) has a limited response to immunotherapy due to its immunologically “cold” tumor microenvironment (TME). Efferocytosis is an important process that regulates the TME, but its mechanism and clinical significance in COAD are unclear.
methodsWe integrated histopathological images, transcriptomic profiles, and clinical data from 387 COAD patients. Image features were extracted using ResNet50 and CellProfiler, followed by construction of a multimodal machine learning model to evaluate prognostic risk. We further combined bulk RNA-seq, single-cell RNA-seq, and spatial transcriptomics to comprehensively characterize efferocytosis-associated immune cell subsets and signaling pathways.
resultsThe efferocytosis-based risk model demonstrated strong prognostic performance across multiple time points and remained independent of conventional clinical indicators. Mechanistically, we identified a subset of STAB1+ tumor-associated macrophages (TAMs) enriched in COAD tumors, exhibiting enhanced efferocytosis activity, M2-like polarization, and mTORC1 signaling activation. In vitro, STAB1 expression was essential for IL-4-induced M2 polarization, and its inhibition attenuated the formation of immunosuppressive TAMs. Single-cell and spatial transcriptomic analyses revealed that this macrophage population was transcriptionally distinct and increased in abundance following neoadjuvant therapy.
conclusionThis study establishes a multimodal prognostic system that integrates histopathological imaging with molecular profiling, and for the first time reveals the pivotal role of STAB1+ TAMs in orchestrating the immunosuppressive TME via efferocytosis and mTORC1 activation. Our findings provide both a clinically applicable risk assessment tool and a potential therapeutic target. Targeting STAB1 may broaden the benefit of immunotherapy for COAD patients with limited responses to immune checkpoint blockade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.